The Latest Breaking News from NVO

The pharmaceutical industry is set for solid growth due to increased demand for effective treatments for regular and rare diseases, an aging population, and ongoing innovations in pharma technology. Hence, investors could consider buying quality pharmaceutical stocks such as Collegium Pharmaceutical (COLL), Novo Nordisk (NVO), and GSK (GSK). Read on.

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

Novo Nordisk is a blue-chip healthcare stock that has delivered game-changing returns to shareholders in the past two decades. Is NVO stock still a good buy?

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

Welcome to IBD Live! This list of FAQs and useful links will speed your learning curve. Some users have reported the inability to access the IBD Live show page on investors.com from their mobile and tablet devices. Please clear your browser cache and relaunch the browser to resolve this issue.…

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.